Published in BMC Immunol on January 09, 2009
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res (2011) 1.61
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology (2011) 1.08
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol (2012) 1.05
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol (2012) 1.03
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
High hydrostatic pressure pre-treatment of whey proteins enhances whey protein hydrolysate inhibition of oxidative stress and IL-8 secretion in intestinal epithelial cells. Food Nutr Res (2012) 0.85
Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis (2010) 0.83
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. Stem Cells Int (2017) 0.77
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. Vaccines (Basel) (2016) 0.75
Nitric oxide and cancer immunity in solid tumor tissues. Immunotherapy (2009) 0.75
Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells. Front Oncol (2015) 0.75
Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64
Studies in antibody response of mice to tumour inoculation. Br J Cancer (1950) 4.52
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 3.45
STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol (2005) 3.32
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods (1994) 2.85
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res (2007) 2.49
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest (1992) 2.22
Chronic nitric oxide inhibition model six years on. Hypertension (1998) 1.72
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer (2006) 1.71
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res (2008) 1.20
A colon tumor model for anticancer agent evaluation. Cancer (1975) 1.17
Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer (1999) 1.08
Arginase activity is inhibited by L-NAME, both in vitro and in vivo. J Enzyme Inhib Med Chem (2002) 1.07
Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol (2003) 1.01
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res (2003) 0.95
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res (2000) 0.94
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 0.89
B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res (1996) 0.83
The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes. Cancer Res (1997) 0.78
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother (2012) 2.22
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol (2008) 1.98
[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging (2008) 1.96
Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol (2011) 1.91
The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. J Urol (2012) 1.68
The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int (2010) 1.60
Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol (2009) 1.60
Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol (2011) 1.58
Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer (2011) 1.56
Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J Urol (2011) 1.53
When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? Int J Urol (2010) 1.52
Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. Stem Cells Transl Med (2013) 1.50
Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma. Eur Urol (2011) 1.47
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. BJU Int (2013) 1.47
Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology (2013) 1.42
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 1.41
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol (2012) 1.25
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res (2008) 1.20
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 1.17
The extent of tumour fat invasion affects survival in patients with renal cell carcinoma and venous tumour thrombosis. BJU Int (2010) 1.10
Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol (2010) 1.08
Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol (2008) 1.06
Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int (2009) 1.05
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol (2002) 1.04
Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med (2012) 1.00
Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience. BJU Int (2008) 0.97
Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores? J Urol (2008) 0.97
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res (2003) 0.95
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology (2013) 0.93
Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res (2004) 0.93
Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res (2013) 0.93
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. Mol Cancer Ther (2008) 0.92
iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS One (2010) 0.91
Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. Cancer Res (2002) 0.89
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 0.89
Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int (2006) 0.87
There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. Prostate (2011) 0.87
Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl (2005) 0.87
Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. Cancer Res (2013) 0.87
The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol (2011) 0.87
Influence of obesity on tumour volume in patients with prostate cancer. BJU Int (2011) 0.86
Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases. J Urol (2009) 0.86
Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol (2004) 0.86
Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma. Mod Pathol (2002) 0.84
Monofocal and plurifocal high-grade prostatic intraepithelial neoplasia on extended prostate biopsies: factors predicting cancer detection on extended repeat biopsy. Urology (2004) 0.84
Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU Int (2010) 0.84
Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer (2011) 0.83
Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology (2006) 0.82
Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. Int J Urol (2009) 0.82
Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys (2009) 0.82
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. Int J Cancer (2013) 0.82
Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin Cancer Res (2011) 0.82
Concurrent allorecognition has a limited impact on posttransplant vaccination. J Immunol (2011) 0.82
Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Urology (2008) 0.82
Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. Int J Cancer (2003) 0.81
Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol (2003) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. Cancer Res (2004) 0.80
Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid beta-cell tumors. Endocrinology (2002) 0.80
Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy. BJU Int (2011) 0.79
Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate (2012) 0.79
Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. Oncoimmunology (2013) 0.79
Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology (2005) 0.79
Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer (2011) 0.79
Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res (2010) 0.79
Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. Prostate (2011) 0.79
Characterization of preclinical models of prostate cancer using PET-based molecular imaging. Eur J Nucl Med Mol Imaging (2009) 0.79
Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study. BJU Int (2011) 0.79
[Role of prostate fossa ultrasonography in the diagnosis of local recurrence after radical prostatectomy in case of PSA failure]. Arch Ital Urol Androl (2002) 0.78